Panacea Biotec arm gets USFDA OAI status for Baddi facility

The US Food and Drug Administration (USFDA) had inspected the Baddi unit of its subsidiary, Panacea Biotec Pharma Ltd (PBPL) from May 30 to June 8, 2022. Subsequently, the USFDA issued Form 483 with eight observations which are related to improvements in existing procedures and are addressable, Panacea Biotec said in a regulatory filing.

According to the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

The company said it has "now received a communication from the USFDA indicating the inspection classification as Official Action Indicated (OAI)".

The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved, it added.

"PBPL is working closely with USFDA to close these observations and the closure of the warning letter issued by the USFDA earlier on September 24, 2020," the filing said.

Read also: Panacea Biotec gets CDSCO nod Pentavalent vaccine for 5 deadly disease

The warning letter was issued for non-compliance with the current good manufacturing practice outlined by the USFDA.

"We are committed to patient safety and quality and take quality and compliance matters seriously and stand by our commitment to fully comply with the cGMP quality standards," the company added.

It further said PBPL continues to manufacture and distribute existing products for the US market, thereby not likely to have any material adverse impact on current business from the facility.

Read also: Panacea Biotec arm gets 8 USFDA observations for Baddi facility